Compositions for immunising against staphylococcus aureus

Patent metadata

Field	Value
Publication number	US-2016158335-A1
Application number	US-201514961772-A
Country	US
Kind code	A1
Filing date	Dec 7, 2015
Priority date	Apr 14, 2009
Publication date	Jun 9, 2016
Grant date	—

Abstract

An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.

First claim

1 - 22 . (canceled)

23 : An immunogenic composition comprising a polypeptide comprising (i) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 186 and/or (ii) a fragment of SEQ ID NO: 186, wherein the fragment of SEQ ID NO: 186 comprises 16 or more consecutive amino acids of the amino acid sequence of SEQ ID NO: 186.

24 : The composition of claim 23 , wherein the fragment comprises 16 consecutive amino acids of the amino acid sequence of SEQ ID NO: 186.

25 : The composition of claim 24 , wherein the fragment comprises 20 consecutive amino acids of the amino acid sequence of SEQ ID NO: 186.

26 : The composition of claim 23 , wherein the fragment lacks the first 20 N-terminal amino acids of SEQ ID NO: 186.

27 : The composition of claim 23 , wherein the composition further comprises one or more of the following S. aureus polypeptides: an esxA antigen; an esxB antigen; an hla antigen; an sta006 antigen; an sta011 antigen; a LukE antigen; and a spa antigen.

28 : The composition of claim 23 , further comprising an adjuvant.

29 : The composition of claim 23 , further comprising: one or more conjugates of (i) a S. aureus exopolysaccharide and (ii) a carrier protein.

30 : The composition of claim 23 , further comprising: one or more conjugates of (i) a S. aureus capsular polysaccharide and (ii) a carrier protein.

31 : A method for raising an immune response in a mammal comprising the step of administering to the mammal an effective amount of the composition of claim 23 .

32 : A polypeptide of formula NH 2 -A-(-X-L-) n -B—COOH, wherein:
X is an amino acid sequence of a staphylococcal antigen sta116;
L is an optional linker amino acid sequence;
A is an optional N-terminal amino acid sequence;
B is an optional C-terminal amino acid sequence; and
n is an integer of 2 or more.

33 : An immunogenic composition comprising the composition of claim 32 and further comprising: (A) one or more conjugates of (i) a S. aureus exopolysaccharide and (ii) a carrier protein; and/or (B) one or more conjugates of (i) a S. aureus capsular polysaccharide and (ii) a carrier protein.

Assignees

• Glaxosmithkline Biolog Sa

Inventors

• Bagnoli Fabio
• Biagini Massimiliano
• Fiaschi Luigi
• Grandi Guido
• Mishra Ravi Pratap Narayan
• Norais Nathalie
• Scarselli Maria

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K14/31

  from Staphylococcus (G) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61K39/085 Primary

  Staphylococcus · CPC title